Overview

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The aim of this study was to compare the efficacy and safety of POF, FOLFOX, and FOLFOX plus paclitaxel(ip) as first-line treatment in AGC a phase II clinical trial.
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Cancer Hospital
Treatments:
Albumin-Bound Paclitaxel
Fluorouracil
Leucovorin
Oxaliplatin
Paclitaxel